Serum Level Of Cartilage Oligomeric Matrix Protein Research Articles

Cartilage Oligomeric Matrix Protein in Osteoarthritis and Obesity-Do New Considerations Emerge?

The diagnosis of osteoarthritis (OA) is based on radiological changes that are delayed, along with clinical symptoms. Early and very early diagnosis at the stage of molecular pathology may eventually offer an opportunity for early therapeutic intervention that may retard and prevent future damage. Cartilage oligomeric matrix protein (COMP) is a non-collagenous extracellular matrix protein that promotes the secretion and aggregation of collagen and contributes to the stability of the extracellular matrix. There are contradictory literature data and currently, the parameter is used only for scientific purposes and its significance is not well-determined. The serum level of COMP in patients with metabolic type OA of the knee has not been evaluated. The aim of the study was to analyze serum COMP levels in metabolic knee OA and controls with different BMI. Our results showed that the mean COMP values were significantly higher in the control group (1518.69 ± 232.76 ng/mL) compared to the knee OA patients (1294.58 ± 360.77 ng/mL) (p = 0.0012). This may be related to the smaller cartilage volume in OA patients. Additionally, COMP levels negatively correlated with disease duration (p = 0.04). The COMP level in knee OA with BMI below 30 kg/m2 (n = 61, 1304.50 ± 350.60 ng/mL) was higher compared to cases with BMI ≥ 30 kg/m2 (n = 76, 1286.63 ± 370.86 ng/mL), but the difference was not significant (p = 0.68). Whether this finding is related to specific features in the evolution of the metabolic type of knee OA remains to be determined. Interestingly, comparison of COMP levels in the controls with different BMI revealed significantly higher values in overweight and obese individuals (1618.36 ± 203.76 ng/mL in controls with BMI ≥ 25 kg/m2, n = 18, 1406.61 ± 216.41 ng/mL, n = 16; p = 0.0092). Whether this finding is associated with increased expression of COMP in the adipose tissue or with more intensive cartilage metabolism in relation to higher biomechanical overload in obese patients, considering the earlier development of metabolic type knee OA as an isolated finding, remains to be determined.

A Comparison between Avocado-Soybean Unsaponifiables and Celecoxib on Serum Levels of Cartilage Oligomeric Matrix Protein in Patients with Knee Osteoarthritis

Background/objectives: Cartilage oligomeric matrix protein (COMP) as a marker of cartilage destruction. We aimed to compare the effect of a mixture of avocado-soybean unsaponifiables versus celecoxib on the serum level of COMP in patients with knee osteoarthritis.Methods: This was a randomized controlled trial and the patients with knee osteoarthritis were recruited from those who attended Imam Reza Hospital, Mashhad, Iran. The patients were divided randomly into two groups; Group 1 (n=30) received avocado+soybean mixture (300 mg daily) and group 2 (n=30) received celecoxib (200 mg/day) for 2 months. At the enrollment and then every month up to 2 months, the patients' venous blood samples were collected to measure serum COMP.Results: The total number of patients was 60 (male 38%, female 62%) with a mean age 56±7 years. Before treatment, the serum levels of COMP were 14.5±1.4 unit/liter (U/L) and 13.9±1.4 U/L in avocado+soybean mixture and celecoxib groups, respectively (P=0.052). After the first month the serum levels of COMP were 12.3±1.5 U/L and 12.8±1 U/L in avocado+soybean mixture and celecoxib groups, respectively (P

Study the role of serum cartilage oligomericmatrix protein (COMP) in the diagnosis of rheumatoid arthritis patients

Background: rheumatoid arthritis (RA) is a systemic autoimmune disease of unknown etiology. Cartilage oligomeric matrix protein (COMP) is one of markers used for early predicting joint destruction and disease activity in RA disease. Objective: in the present study we evaluated the role of COMP as diagnostic marker in RA patients in comparison with other traditional markers and its correlation with disease activity parameters. Patients and Methods: blood samples were collected from 50 patients newly diagnosed with rheumatoid arthritis (Group I) and also from 30 healthy subjectsas a control group (Group II).Serum level of COMP was measured by enzyme-linked immunosorbent assay (ELISA). Results: there was a high significant difference between the RA patients group and the control group regardingserum COMP level. Also, there was a significant correlation between serum COMP level with clinical and laboratory data of active RA patients. Conclusions: serum COMP could be useful for early diagnosis of rheumatoid arthritis and also could be used as a marker of disease activity and joint destruction.

Serum Cartilage Oligometric Matrix Protein and Pettersson Scoring System As an Index for Hemophilic Arthropathy

▪The pathogenesis of hemophilic arthropathy is multifactorial, with changes occurring in the synovium, bone, cartilage, and blood vessels. Recurrent joint bleeding causes synovial proliferation and inflammation (hemophilic synovitis) that contributes to end stage degeneration (hemophilic arthropathy); with pain and limitation of motion that severely affects patients’ quality of life.The aim of the present study was to evaluate the degree of joint damage in boys with hemophilia using plain x-ray, and to measure serum level of human cartilage oligomeric matrix protein, to determine its relation to the degree of joint damage.The study was carried out on thirty boys with hemophilic arthropathy (group I) and ten healthy boys were included as control (group II).All hemophilic patients were scored for Functional independence score (FISH score) in hemophilia and radiological changes (Pettersson’s score) using conventional frontal and lateral radiographs of the most affected joint.Factor activity level was measured for all hemophilic patients while serum cartilage oligomeric matrix protein (COMP) was measured for hemophilic patients and control group.Among the thirty hemophilic patients, 26 (86.7%) patients were hemophilia A and 4 (13.3%) patients were hemophilia BAll patients were receiving on demand replacement therapy using plasma derived Factor concentrate or fresh frozen plasma (FFP) according to availability.Fifteen patients (50%) had severe hemophilia, 7 (23.3%) had moderate and 8(26.72%) had mild hemophilia.A higher serum level of COMP with a mean of 757± 211.30 in the severe hemophiliacs, and a mean of 403.57 ± 86.49 and 211.25 ± 74.26 in the moderate and mild hemophiliacs respectively the difference was statistically significant (p < 0.001).Serum level of COMP in group I was significantly higher than in group II (p=0.004) with significant negative correlation with FISH score (r=-0.435 p=0.016). COMP correlated positively with joint space narrowing of the Pettersson score (r=0.421 p<0.001) and with total Pettersson score (r=0.421 p=0.020).The number of joints affected (during life) of hemophilic patients ranged between 1-12 with a mean of 5.50 ± 2.46 Joints. A significant positive correlation between serum level of COMP and number of joints affected (r = 0.487, p = 0.006).Joint space narrowing is the most important indicator of cartilage loss. Serum COMP level is indicative of the amount of joint damage in patients with hemophilic arthropathy.The combined scoring of functional independence and Pettersson in addition with serum levels of COMP give a good overview of the degree of hemophilic arthropathy DisclosuresNo relevant conflicts of interest to declare.

Serum Cartilage Oligomeric Matrix Protein (COMP) Estimation: A Tool to Assess Efficacy of Treatment in Knee Osteoarthritis

Context: Osteoarthritis is a leading cause of disability in older adults. Various treatment options present, ranging from lifestyle modification to total knee replacement. What is the effect of on-going treatment over disease and at what stage the patient requires change of therapy is the questions which still need to be answered. Developing an investigatory modality to provide information about efficacy of on-going treatment is the need of the hour. Aim: Aim of present study is to estimate and compare serum levels of Cartilage Oligomeric Matrix Protein (COMP) for assessing efficacy of treatment and disease prognosis in patients having knee osteoarthritis. Settings and Design: It is a prospective randomized control trial which was conducted in the Department of orthopedics, in a tertiary care teaching hospital in Northern India within a period of two year recruiting 100 cases. Methods and Materials: All the cases were asked to fill the WOMAC questionnaire and Kellgren Lawrence (KL) Grading was done for all. The serum level of COMP was estimated by ELISA. The value of serum COMP was compared with WOMAC score and KL grading scale. The cases were prescribed medications according to standard management guidelines of OARSI. Follow up was done after every four weeks to assess the efficacy of treatment and disease progression. Results: The level of increase in Serum COMP corresponds to the severity of disease, and radiological staging. In almost all treatment groups Serum COMP level exhibited a downward trend which is gradually regressive with increasing time and continued therapy. In mild cases, the patients treated with Diacerin and lifestyle modification showed best results clinically and in lab values. In moderate cases, the patients treated with Diacerin, Glucosamine with MSM and lifestyle modification showed best results clinically and in lab values. In severe cases, patients treated with Diacerin, Glucosamine with MSM showed best results clinically and in lab values. Conclusion: Serum COMP levels can be used as a prognostic and therapeutic indicator of knee osteoarthritis. The Serum COMP levels give a quantitative explanation about the effectiveness of ongoing treatment. In both mild and moderate knee osteoarthritis, combination of lifestyle modification with pharmacotherapy is superior over pharmacotherapy alone. In severe cases serum COMP values show least improvement, which indicates about limited control of pharmacological therapy in these patients.

Relations of Serum COMP to Cardiovascular Risk Factors and Endothelial Function in Patients with Rheumatoid Arthritis Treated with Methotrexate and TNF-α Inhibitors

To examine whether serum level of cartilage oligomeric matrix protein (S-COMP) is related to methotrexate (MTX) or to MTX and tumor necrosis factor-α (TNF-α) combination treatment for rheumatoid arthritis (RA); and to investigate whether S-COMP is related to cardiovascular risk factors including endothelial dysfunction and level of anticitrullinated protein antibodies (ACPA) in patients with RA. Clinical and laboratory measures, including S-COMP and reactive hyperemic index (RHI), were examined in 55 consecutive patients with RA starting with either MTX (n = 34) or MTX and anti-TNF-α treatment (n = 21) at baseline, and after 6 weeks and 6 months. S-COMP was similar in the 2 treatment regimens during followup. We found a positive relationship between S-COMP at baseline and the use of disease-modifying antirheumatic drugs the last year preceding the study (p = 0.001), and a negative relation to current use of systemic glucocorticosteroids (p = 0.044). The nonsignificant change in S-COMP between baseline and the 6-month followup was positively and independently related to change in ACPA level (p = 0.009). There was no significant association between RHI and level of S-COMP at baseline. The cartilage turnover marker S-COMP did not change significantly after 6 months' treatment with MTX with or without a TNF-α inhibitor in patients with RA. The positive association between S-COMP and ACPA suggests that these factors might interact, and could both be contributors to an unknown link between inflammation and cartilage destruction in patients with RA. S-COMP was not related to endothelial function in patients with RA, or to other cardiovascular risk factors studied. Clinical Trials registration number NCT00902005.

Gene and Protein Expression of Cartilage Oligomeric Matrix Protein Associated with Oncogenesis in Canine Tumors

To investigate the expression of cartilage oligomeric matrix protein (COMP) associated with oncogenesis, samples of serum and tumor tissue were obtained from 25 dogs with tumors. The serum levels of COMP in dogs with tumors were significantly higher than in 38 normal controls and correlated with the concentrations of tumor tissue extracts. Positive bands to COMP antibody were detected on immunoblots of tumor extracts. Immunohistochemistry and in situ hybridization demonstrated positive signals of COMP and its mRNA in the cytoplasm of tumor cells from mammary gland tumors, but not in the normal mammary gland. Positive immunohistochemistry results were also obtained for COMP in mast cell tumor and melanoma cells. Oncogenesis might augment production of COMP and the serum level of COMP in dogs.